Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat
Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt.
The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a
While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can
As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla.
Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker and awards judge Heather Moses – head of medical affairs at Roche – what she is looking for in winning patient init